Healthcare advertising compliance now reaches far beyond the wording of an advert. Healthcare organisations are working across medicines rules, AI assisted monitoring, platform restrictions, health data, pricing, reviews, provider requirements and the complete digital customer journey.
WLW FUTURE reviewed the current public position across the ASA, MHRA, GPhC, CQC, ICO, CMA and PMCPA alongside the healthcare advertising policies published by Google, Meta and TikTok. The aim is to give healthcare leaders and marketing teams one joined view of where current exposure sits and where compliant growth remains possible.
The practical point is simple. Healthcare advertising compliance is no longer a single approval check at the end of a campaign. The offer, claim, audience, channel, landing page, website, customer data and organisation delivering the service can each change the answer.
Research boundary
This is a WLW FUTURE business and marketing report built from current public regulatory, enforcement and platform sources. It is not legal, clinical or regulatory advice. The evidence should be rechecked before campaigns are launched because rulings and platform policies continue to change.
This is a WLW FUTURE business and marketing report built from current public regulatory, enforcement and platform sources. It is not legal, clinical or regulatory advice. The evidence should be rechecked before campaigns are launched because rulings and platform policies continue to change.
60mads processed by the ASA’s Active Ad Monitoring system during 2025
95k+unique paid ads analysed in the ASA weight management enforcement project
11.5%of assessed liquid BBL ads complied by December 2025 in the ASA monitoring project
9,340paid fertility clinic ads reviewed across Google and Meta in the ASA project
The headline findings
The current evidence points to a healthcare advertising environment where proactive monitoring is scaling, prescription medicine promotion is receiving sustained scrutiny and marketing teams need to assess the complete customer journey rather than the advert in isolation.
Monitoring is becoming continuous
The ASA says its Active Ad Monitoring system processed around 60 million ads during 2025 and supported more than 30 regulatory projects.
Indirect medicine references matter
MHRA decisions in 2026 show that wording such as weight loss injections or GLP-1 medication can create a problem where it is likely to lead the public to request a prescription only medicine.
Platform rules add another layer
Google, Meta and TikTok apply their own healthcare restrictions. A campaign can satisfy the UK regulatory framework and still be ineligible on a particular platform.
Health data can create marketing risk
The ICO identifies health information as special category data and says explicit consent is required where special category information is used for direct marketing.
Websites are part of the compliance journey
CQC rating display, price transparency, reviews and the presentation of commercial information can create separate obligations beyond the advert itself.
Compliance still leaves room to grow
Healthcare organisations can build demand through clearer service propositions, useful organic content, stronger customer journeys and better evidence around the claims they make.
What changed in healthcare advertising during 2026
The clearest change is operational. Marketing teams now need to assume that healthcare advertising can be found and assessed at scale rather than relying on complaints to trigger scrutiny. The ASA’s AI assisted monitoring, MHRA investigation programme and sector specific enforcement work create a much more active environment.
At the same time, regulation is intersecting more directly with customer journey design. A compliant paid advert can still lead into a problematic landing page. A lawful healthcare service can still be advertised in a way that promotes a prescription only medicine. A legitimate customer database can still create risk if health information is reused for marketing without the correct basis.
Current public evidence shows the direction of travel
The examples below are not an exhaustive list of UK healthcare enforcement. They show the areas receiving particularly visible attention in the current evidence reviewed for this report.
60mads processed by Active Ad Monitoring during 2025ASA Annual Report 2025
~900weight management ads from 38 advertisers assessed as likely to breach the rulesASA weight loss POM report
2026MHRA decisions continue to distinguish lawful service promotion from public promotion of POMsMHRA advertising investigations
Promoting a healthcare service is different from promoting a medicine
This is one of the most useful distinctions for healthcare marketers. A provider may be able to promote a consultation, treatment service or access route in circumstances where the prescription only medicine used within that service cannot be advertised to the public.
CAP Code rule 12.12 states that prescription only medicines or prescription only medical treatments may not be advertised to the public. The MHRA’s 2026 weight management decisions go further into the practical boundary by examining wording and imagery which can indirectly lead a member of the public towards a particular prescription medicine.
The wording matters
A named product is the obvious case. Indirect references can also matter. Current MHRA decisions discuss wording such as GLP-1 medication and weight loss injections alongside the complete presentation and likely effect of the advert.
A named product is the obvious case. Indirect references can also matter. Current MHRA decisions discuss wording such as GLP-1 medication and weight loss injections alongside the complete presentation and likely effect of the advert.
Named medicine
A named prescription only medicine in public facing advertising is an immediate high risk trigger for review.
Implied medicine
Drug classes, injection wording, branded pen imagery and similar cues can still create a medicine promotion issue.
Service led advertising
The consultation, access route or healthcare service can be the commercial proposition where the rules permit it.
The destination matters
The landing page, pricing presentation and customer journey after the click can change the compliance and platform assessment.
Choose your healthcare sector
The underlying rules do not apply identically to every healthcare organisation. Select a sector below to bring the most relevant current risks and commercial opportunities to the front.
Healthcare sector explorer
This is a practical marketing view rather than a substitute for the complete regulatory framework applying to the organisation.
Private healthcare
Mixed riskMarketing risk is usually driven by the treatment, claims, pricing, provider status and whether prescription only medicines enter the journey.
Watch
- Treatment and outcome claims
- Pricing and unavoidable fees
- Testimonials and reviews
- CQC rating display where applicable
Opportunity
- Clear service scope
- Visible clinical credibility
- Transparent next steps
- Search and AI content around real patient questions
Online pharmacy
High scrutinyPrescription medicine promotion, discount mechanics, prescribing governance and platform certification need to be checked together.
Watch
- Prescription medicine promotion
- Medicine specific discounts
- Online prescribing claims
- Google certification
Opportunity
- Service led promotion where permitted
- Trust around prescribing governance
- Useful condition and service content
- Clear customer journeys
Weight management
High scrutinyCurrent ASA and MHRA activity makes indirect POM references, injection language, GLP-1 wording and product imagery priority review areas.
Watch
- Named POMs
- GLP-1 references
- Weight loss injection wording
- Branded pen imagery
- Pipeline product promotion
Opportunity
- Service led advertising where permitted
- Clear eligibility journeys
- Educational content
- Organic search visibility
Telemedicine
High scrutinyRemote care combines treatment claims, prescription service rules, platform certification, provider governance and health data.
Watch
- Remote diagnosis claims
- Prescription service promotion
- Clinical scope
- Platform certification
- Health data
Opportunity
- Explain the care pathway clearly
- Build trust and governance content
- Use permitted service advertising
- Improve mobile conversion
Fertility
Claims sensitiveSuccess rates, prices, add ons, comparative claims and emotionally sensitive decision making are central advertising risks.
Watch
- Success rates
- Price claims
- Add ons
- Complementary therapies
- Best or leading claims
Opportunity
- Evidence led claims
- Complete price information
- Clear outcome measures
- Responsible differentiation
Cosmetic and aesthetic clinics
High scrutinyPOM rules, under 18 targeting, social responsibility, urgency, body image and medical risk claims all need active review.
Watch
- Prescription only treatments
- Under 18 targeting
- Time limited offers
- Downplaying medical risk
- Body image pressure
Opportunity
- Responsible service promotion
- Evidence based claims
- Transparent practitioner information
- Better consultation journeys
Health technology
Claims sensitiveThe key boundary is often whether a wellbeing feature becomes a medical, diagnostic, monitoring or treatment claim.
Watch
- Medical versus wellness claims
- Device status
- Diagnostic and monitoring claims
- Claims that discourage essential treatment
Opportunity
- Define product scope precisely
- Separate wellbeing from medical claims
- Make evidence visible
- Explain regulatory status clearly
Pharmaceutical and regulated healthcare
High scrutinyPublic information, promotion, press activity, employee social posts, HCP communications and certification need clear governance.
Watch
- Public promotion of POMs
- Press releases and earned media
- Employee social posts
- Balance and substantiation
- Certification
Opportunity
- Separate public information and promotion
- Build strong internal review governance
- Audience specific HCP communication
- Compliant disease awareness content
Run a quick healthcare marketing compliance screen
The questions below are designed to identify obvious areas requiring closer review. The result is a marketing risk screen. It does not determine whether an advert is legally compliant.
Where does your campaign need the closest review?
Choose the closest answer for each question. The result changes as you work through the form.
Review required
Check the service, channel and landing page together
Healthcare service advertising can still require careful claims, platform and provider checks. Review the advert and the destination as one customer journey.
Google, Meta and TikTok can apply different healthcare rules
Platform eligibility should be treated as a separate approval layer. The position below summarises the public UK policy pages reviewed for this report.
| Channel | Current public policy position | Practical marketing implication |
|---|---|---|
| UK online pharmacies and qualifying telemedicine prescription drug services can be promoted with limitations and certification. Google says prescription drugs cannot be promoted in the ads and landing pages. | Check provider eligibility, Google certification and the complete destination before building media around prescription services. | |
| Meta | Meta’s current public prescription drug policy lists the United States, Canada and New Zealand as eligible countries for authorised prescription drug advertising. The UK is not listed. | General healthcare or telehealth promotion needs to be separated from prescription drug promotion and checked against Meta’s wider policies. |
| TikTok | TikTok’s June 2026 UK policy lists prescription medicines as not allowed. Some OTC medicines and medical devices may be permitted subject to requirements. | Do not assume a healthcare category approved elsewhere can be transferred to TikTok without a fresh policy review. |
| SEO and owned content | Owned pages can still become marketing communications and remain subject to claims and medicines rules. | Use organic content for depth and genuine patient questions, with evidence and clear separation between information and promotion. |
| Email and CRM | The ICO treats health information as special category data. Direct marketing using special category data requires particular care and explicit consent in the situations described by the ICO. | Map forms, CRM fields, website behaviour, audiences and profiling before using health related information to personalise marketing. |
Recent enforcement shows where the pressure is building
Healthcare enforcement is spread across different regulators and self regulatory bodies. These examples show the range of current issues marketing teams should be watching.
PMCPA sanctions published in Sanofi cases
Cases included findings concerning public promotion of a prescription only medicine through press coverage, a press release and related employee social activity.
PMCPAMHRA publishes June advertising decisions
The current collection includes weight management, general medicinal treatment services and hay fever treatment services.
MHRAJoint warning on new and unlicensed weight management medicines
MHRA, ASA and GPhC warned about promotion of newly authorised medicines and products which did not yet have a marketing authorisation.
Joint regulator warningASA publishes health monitoring app rulings
Rulings dealt with medical claims, device status and claims that smartphone apps could monitor blood pressure.
ASA weight loss POM enforcement report
More than 95,000 unique paid ads from 44 advertisers were analysed. Around 35,000 related to weight management and around 900 ads from 38 advertisers were assessed as likely to break the rules.
ASAASA liquid BBL enforcement report
The ASA captured 928 unique Meta ads between April and December 2025. Only 11.5% of assessed ads complied with the social responsibility rules by December 2025.
ASAThe advert is only one part of the healthcare customer journey
Healthcare marketing teams need to look beyond creative approval. Website information, pricing, reviews and marketing data can create separate compliance or consumer protection questions.
CQC rating display
Where Regulation 20A applies and a provider has received a CQC rating, current CQC guidance sets out website display requirements.
Price transparency
CMA guidance updated in January 2026 covers total price presentation and illegal drip pricing involving unavoidable charges added later in the journey.
Reviews and commercial presentation
The wider unfair commercial practices framework can affect reviews, endorsements, comparative claims, pressure selling and the presentation of commercial relationships.
Health data and audiences
A condition page visit, questionnaire response or treatment enquiry can reveal health information. Reusing that information for advertising or CRM segmentation requires a separate data protection assessment.
Where compliant healthcare marketing can still grow
Compliance should make the marketing system more precise. Healthcare organisations still have substantial room to improve visibility, trust, customer journeys and conversion without relying on aggressive or poorly governed promotion.
Build service led propositions
Where medicine promotion is restricted, focus on whether the consultation, service, access model, expertise and customer journey can be communicated compliantly.
Use search for depth
Condition, service and decision content can answer genuine questions with evidence without forcing every commercial message into paid creative.
Design compliance into conversion
Pricing, credentials, next steps, provider information and data handling can strengthen trust while reducing avoidable ambiguity.
Keep evidence with the claim
Maintain substantiation, approvals and source dates so the team can explain why a claim was used and know when it needs review.
Separate channel checks
Record both the UK compliance position and the advertising platform eligibility position before committing media spend.
Monitor after launch
ASA rulings, MHRA decisions and platform policies change. Campaign governance needs a live review stage after activation.
Score your current healthcare marketing setup
This diagnostic is designed to expose gaps between creative approval, channel eligibility, claims evidence, website obligations and marketing data.
How much of the compliance system is built into your marketing?
Tick each statement only where it is genuinely true across the relevant people and channels.
0/8
Start with the fundamentals
The current setup appears to rely on manual judgement or disconnected checks. Build a documented approval and monitoring route before increasing healthcare media activity.
Explore the WLW healthcare intelligence series
This report is the master compliance view. The specialist 2026 benchmarks below go deeper into the markets where regulation, customer journey design, search visibility and commercial growth intersect.
Private healthcareRecord private admissions, NHS waiting pressure, pricing, trust, booking, patient acquisition and digital growth.
Online pharmacyGPhC inspection themes, POM promotion, remote prescribing, platform rules, health data and digital growth.
Weight managementGLP-1 and POM advertising, ASA and MHRA enforcement, platform rules, customer journeys and compliant growth.
TelemedicineCQC and GMC requirements, remote prescribing, platform eligibility, health data, trust and customer journeys.
Fertility clinicsASA monitoring, HFEA success rates, pricing, treatment add-ons, virtual clinics and patient acquisition.
Cosmetic and aesthetic clinicsBotox and POM rules, under 18 targeting, treatment claims, platform restrictions and consultation journeys.
Health technology and pharmaceuticalAI medical devices, MHRA regulation, ABPI promotion, regulated claims, evidence, health data and buyer journeys.
Supporting WLW healthcare research
These articles provide additional evidence, market context and specialist advertising analysis around the main 2026 benchmarks.
Restricted healthcare advertisingHow to keep marketing active when healthcare categories carry additional advertising restrictions.
ASA monitoring and online pharmacyHow proactive advertising monitoring changes the risk for pharmacy marketing teams.
Online pharmacy advertising risksCommon POM, landing page, registration and platform problems in pharmacy acquisition.
Healthcare advertising rejection and complianceWhy healthcare campaigns are rejected and how claims, platforms and landing pages interact.
NHS queues and self pay healthcareHow public waiting pressure is changing private healthcare demand and patient behaviour.
NHS delays and self pay trendsSupporting facts on patient behaviour, regional demand, payment and the move into private care.
Browse all healthcare researchSee the complete WLW FUTURE healthcare archive and the latest published research.
WLW FUTURE healthcare digital opportunity review
Find the compliance risks and the growth opportunities in the same review
WLW can review advertising, landing pages, customer journeys, search visibility, AI visibility, channel eligibility, pricing presentation and marketing data together. The outcome is a prioritised view of what needs attention and where marketing can move forward.
Request a healthcare digital opportunity reviewFrequently asked questions
Can a UK healthcare provider advertise a prescription treatment?
CAP Code rule 12.12 says prescription only medicines or prescription only medical treatments may not be advertised to the public. A healthcare organisation may be able to promote a service or consultation depending on the circumstances, but the advertising must not become promotion likely to lead to use of a prescription only medicine.
Can a weight management advert say GLP-1 or weight loss injection?
MHRA advertising decisions during 2026 specifically discuss indirect references including GLP-1 medication and weight loss injections where those references are likely to lead a member of the public to request a prescription only medicine. Treat this wording as a high priority review area.
Can an online pharmacy advertise on Google in the UK?
Google’s current policy says UK online pharmacies may advertise with limitations where they are registered with the GPhC and certified by Google. Google also states that prescription drugs cannot be promoted in the ads and landing pages.
Can a UK telemedicine company advertise prescription drug services on Google?
Google’s current policy says qualifying UK telemedicine providers may promote prescription drug services with limitations where they hold the specified LegitScript Healthcare Merchant certification and Google certification. Prescription drugs cannot be promoted in the ads and landing pages.
Does Meta allow UK prescription drug advertising?
Meta’s current public prescription drug policy lists the United States, Canada and New Zealand as the eligible countries for authorised prescription drug advertising. The UK is not listed.
Can TikTok be used for healthcare advertising in the UK?
Yes for some healthcare categories, subject to TikTok’s market specific restrictions. Its June 2026 policy lists prescription medicines as not allowed in the UK and sets conditions for categories such as OTC medicines and medical devices.
Can healthcare marketing use patient health data to build audiences?
Health information is special category data. The ICO says organisations should have explicit consent if they want to use special category information for direct marketing and warns that profiling for targeting can involve special category data.
Does CQC rating display affect the website?
Where Regulation 20A applies and the provider has received a CQC rating, current CQC guidance requires the rating to be displayed conspicuously and legibly on the website.
Is healthcare advertising compliance only an ASA issue?
No. Depending on the organisation and activity, the framework can involve the MHRA, ASA and CAP, GPhC, CQC, PMCPA, ICO, CMA, professional codes and individual advertising platform rules.
How often should healthcare marketing compliance be reviewed?
Build review into planning, pre launch approval and live monitoring. ASA rulings are published regularly, MHRA publishes advertising investigation decisions and advertising platform policies can change independently.
Sources and evidence review
- CAP Code Section 12. Medicines, medical devices, health related products and beauty products.
- ASA Annual Report 2025. Used for Active Ad Monitoring scale and regulatory project context.
- ASA weight loss prescription only medicines Enforcement Report.
- ASA non surgical liquid BBL Enforcement Report.
- ASA fertility clinic Enforcement Report.
- MHRA advertising investigations collection.
- MHRA Blue Guide.
- MHRA, ASA and GPhC joint warning, June 2026.
- PMCPA sanctions release, 21 July 2026.
- ICO direct marketing guidance.
- CQC Regulation 20A guidance.
- CMA price transparency guidance.
- Google healthcare and medicines advertising policy.
- Meta drugs and pharmaceuticals advertising policy.
- TikTok healthcare and pharmaceuticals advertising policy.
Update note: Regulatory and platform sources describe different legal frameworks, enforcement programmes and commercial policies. They have not been merged into a single legal test. The interactive features are practical marketing screens built from those separate sources.
